INVO Fertility realigns executive leadership, appointing new CFO and strategic Chief Business Officer to drive growth
IVF sits 34% above its 52-week low of $0.71.
Summary
INVO Fertility announced a strategic executive leadership realignment, promoting Terah Krigsvold to CFO and appointing former CFO Andrea Goren as Chief Business Officer and CEO of its INVO Centers subsidiary to focus on growth initiatives.
Key Events · Executive and Board Changes · IVF
-
New Chief Financial Officer Appointed
Terah Krigsvold, previously the Company's controller, has been appointed as the new Chief Financial Officer, effective December 30, 2025, with an annual salary of $250,000.
-
Former CFO Transitions to Strategic Growth Role
Andrea Goren resigned as CFO and was appointed Chief Business Officer and CEO of INVO Centers, LLC, a wholly-owned subsidiary. This move leverages his M&A experience to focus on acquisitions and new clinic launches, with an annual salary of $250,000.
-
Executive Realignment Supports Growth Strategy
The leadership changes are designed to align human resources with the Company's growth strategy, aiming to strengthen its ability to execute plans for business expansion and profitability.
Analysis · IVF · Industrial Applications And Services
INVO Fertility, a micro-cap company, has strategically restructured its executive team to bolster its growth strategy, particularly in acquisitions and new clinic launches. The promotion of Terah Krigsvold from controller to Chief Financial Officer ensures continuity and stability in the finance department. Concurrently, former CFO Andrea Goren's transition to Chief Business Officer and CEO of INVO Centers, LLC, a wholly-owned subsidiary focused on fertility clinics, is a significant move. This change leverages Mr. Goren's extensive experience in capital raising and mergers and acquisitions, directly supporting the company's stated goal of expanding its presence in the fertility sector. The company explicitly stated that Mr. Goren's resignation as CFO was not due to any disagreements, mitigating potential negative interpretations and reinforcing the strategic nature of the realignment. This leadership shift is a positive signal for investors, indicating a focused effort to execute on its growth objectives.
At the time of this filing, IVF was trading at $0.95 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $0.71 to $299.52. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.